>
Your Opportunity to Weigh In on Federal Vaccine Policy - Deadline Sunday Sept 20
Palantir $PLTR CEO Alex Karp says "AI companies have to be nationalized"
It's infuriating that they know better, but sell us out until they leave
World's smallest CT scanner fits in the palm of your hand
The Tesla Roadster will blow people's minds
Peter Thiel-Funded Company Anduril to Triple the Number of Autonomous Surveillance Towers...
Quantum computing may soon become part of the microscope itself.
Volkswagen Just Unveiled The Most Efficient EV Ever Tested
NASA Super Light Solar Sail Project Will Be 12-40 Times Lighter and Faster
Space Telescope Interferometer to Image Exoplanet Continents
Twenty-five years of "temporary": how 9/11 built a surveillance state Americans never vote
I'll Never Buy Another WALMART Battery!
Shoei GT-Air 3 Smart helmet drops with built-in AR for $1,500

From hepatitis to cirrhosis there are over 100 different individual conditions that result in damage to the liver. Collectively, liver diseases have been dramatically rising in the United States over the past decade. Damage to liver cells is generally permanent, and if severe enough the only effective treatment is a complete liver transplant.
New research suggests an entirely new treatment for liver disease in the future could eliminate the need for liver transplants by essentially regenerating diseased or damaged liver cells. Utilizing a method called single-cell RNA sequencing the researchers closely studied human fetal and adult livers and discovered a specific type of cell, called a hepatobiliary hybrid progenitor cell (HHyP).
In utero, when a fetus is developing, HHyP cells act as precursors to the two main types of mature liver cells, hepatocytes and cholangiocytes.